7210 Wareham Drive, Tampa, FL 33647
May 1, 2025 The National Consumers League (NCL) – a leading non-profit fighting fraud in the marketplace – today released a white paper as a blueprint for policy changes to combat the flood of false information circulating online about GLP-1 products and launched an ambitious national anti-disinformation effort called the Weight Truth with the online […]
April 24, 2025 The U.S. Census of Service Industries is performed every 5 years, with the last government survey performed in 2022. Commercial weight loss companies (“diet & reducing centers”) are classified under NAICS code 812191 (other personal services). Establishment and firms data for this industry have just been released (see census.gov). This information is
2022 Census Data Published: Commercial Weight Loss Industry Statistics Read More »
April 12, 2025 We noticed a post on Instagram today that pitches a company that will set up a medical weight loss program, using GLP-1 drugs for gyms. We shouldn’t be surprised. Everyone else has entered the GLP-1 gold rush, including med spas, so why not gyms as well? The company offering this “opportunity” is
Gyms Start Selling GLP-1 Drugs? The Bandwagon Gets More Crowded Read More »
April 2, 2025 Robard, the medical weight loss company, has begun selling its shakes, puddings, soups and beverages direct to the public via a new website. These products are part of its New Direction program. This is a departure from its long-standing policy where you had to sign up for the program to get access
Robard Begins Selling Diet Foods Direct to Consumers Read More »
Feb. 27, 2025 WW reported its Q4 and full year 2024 results today. The company’s Board of Directors named Interim President and CEO Tara Comonte, to a permanent role as President and CEO, effective February 26, 2025. “We are pleased with the momentum in our Clinical business in the Fourth Quarter, reflecting the increasing demand
Weight Watchers Reports Q4 and 2024 Yearly Results Read More »
Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of GLP-1 Drugs on Doctors, Hospitals, Clinics and Franchises”, February 2025. This report presents a complete picture of the medical weight loss market in the United States, with the inter-relationships between competing
$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report Read More »
Feb. 18, 2025 “This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,” said Dan Chard, Chairman & CEO. Fourth quarter 2024 revenue decreased 37.7% to $119.0
Medifast Reports Q4 and Full Year 2024 Results Read More »
Feb. 3, 2025 Support for the wildly popular weight loss meds in the new administration appears to be a question mark. Dr. Oz has publicly praised GLP-1s for their benefits, even pitching them on TV and social media channels, according to a Dec. 30 report from The Hill. On the other hand, Mr. Kennedy expressed
Conflicts in Trump Administration For Support of GLP-1 Meds Read More »
January 27, 2025 Shortages is that they don’t last forever, and that applies to compounded weight loss meds. After some legal wrangling, the FDA pulled tirzepatide from its shortage list in December, giving compounders a short grace period to wrap things up. That means people taking the copycats will soon need to switch to the
The Party Is Almost Over for GLP-1 Compounders Read More »
Dec. 20, 2024 The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become wildly popular with Americans trying to lose weight. Zepbound is FDA-approved to treat obesity and Mounjaro is approved for diabetes. They
FDA Says Shortage Is Over, Compounders Have 60-90 Days Read More »